Written by Ashton Snyder on
 May 10, 2024

Neuralink's Initial Human Implant Trial Faces Critical Challenges, Reports Indicate

A Daily Mail report revealed that the first patient to receive Elon Musk's Neuralink implant experienced a life-threatening condition during surgery, which later led to a malfunction of the brain chip.

Following a problematic surgery that introduced air into his skull, Neuralink persisted with their trials, showing notable technological enhancements.

In January 2023, Nolan Arbaugh underwent a pivotal operation involving Neuralink's brain chip implantation. Conducted by a robot that executed precise movements akin to a sewing machine, the 30-minute procedure aimed to restore some independence to Arbaugh, paralyzed since a 2016 car accident.

Pneumocephalus Incident Raises Surgical Concerns

However, post-surgery, Arbaugh suffered from pneumocephalus, a serious condition where air trapped within the skull can lead to complications like seizures or even death. This condition necessitated urgent medical attention and sparked internal debates at Neuralink about the feasibility of continuing with the implanted device.

The implant, designed to enhance Arbaugh's ability to perform daily tasks independently, initially malfunctioned when some of the 64 threads retracted from his brain, decreasing the device's functionality. Despite these hurdles, Neuralink adjusted its technology to improve sensitivity to neural signals, which significantly enhanced Arbaugh's control over a computer cursor.

Regulatory Engagement and Technological Adjustments

Neuralink's dialogue with the FDA was crucial in addressing and resolving the complications arising from the surgery. The adjustments made to the recording algorithm of the Link, the chip's name, allowed for better interaction with the user interface, thereby improving Arbaugh's quality of life.

As a paraplegic, Arbaugh's only means of communication before the implant was a mouth-held tablet stylus. Post-implant, he expressed significant comfort gains, using a laptop to browse the internet, play games, and post on social media from his bed without physical assistance.

Continued Trials and Future Endeavors

Despite the setbacks, Neuralink has continued with its trials and plans to expand the number of participants. With ten individuals lined up for the year, the company aims to refine its procedures and enhance the chip's capabilities further.

Gav Martell, cofounder of Yonalink, remarked on the nature of clinical trials, emphasizing that while challenges like the retraction of threads are significant, they provide crucial learning opportunities that drive technological and procedural refinements.

Participant's Life Transformations and Company's Response

Arbaugh's daily life has been substantially transformed by the Link, which allows him up to 8 hours of research contributions during weekdays and over 10 hours of personal activities on weekends. This engagement highlights the potential impact of Neuralink's technology on lives severely restricted by physical disabilities.

Neuralink's history with animal testing, involving the use of substances like "Bioglue" and the resulting fatalities among tested animals, underscores the experimental nature of their research and the lengths to which the company has gone to refine their technology.

Arbaugh himself finds significant value in the independence afforded by the Link. "The biggest thing with comfort is that I can lie in my bed and use [the Link]. It lets me live on my own time," he said, appreciating the ability to manage daily activities without constant assistance.


While Neuralink's initial foray into human brain chip implantation has faced significant challenges, the adjustments made and the continued trials highlight the potential of such technology to transform lives. The experiences of Nolan Arbaugh serve as a testament to both the possibilities and the hurdles inherent in pioneering medical technology.

Author Image

About Ashton Snyder

Independent conservative news without a leftist agenda.
© 2024 - American Tribune - All rights reserved
Privacy Policy